Sign in
4

Changes in Ownership

Roivant Sciences Ltd. Filed Acc 0001140361-25-035890

President & Immunovant CEO sold 1,711,000 shares at an average $14.92 ($25,524,777)

  • President & Immunovant CEO acquired 1,562,374 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Venker Eric President & Immunovant CEO 2025-09-19 Option exercise 10b5-1 +1,000,000 $3.85 $3,850,000 2,653,585 D
Venker Eric President & Immunovant CEO 2025-09-19 Sale 10b5-1 −683,818 $14.95 $10,223,079 1,969,767 D
Venker Eric President & Immunovant CEO 2025-09-22 Option exercise 10b5-1 +462,374 $3.85 $1,780,140 2,432,141 D
Venker Eric President & Immunovant CEO 2025-09-22 Option exercise 10b5-1 +100,000 $3.85 $385,000 2,532,141 D
Venker Eric President & Immunovant CEO 2025-09-22 Sale 10b5-1 −316,182 $14.99 $4,739,568 2,215,959 D
Venker Eric President & Immunovant CEO 2025-09-22 Sale 10b5-1 −100,000 $15.01 $1,501,000 2,115,959 D
Venker Eric President & Immunovant CEO 2025-09-23 Sale 10b5-1 −611,000 $14.83 $9,061,130 1,504,959 D
Derivatives
Venker Eric President & Immunovant CEO 2025-09-19 Option exercise · Stock Option (Right to Buy) 10b5-1 −1,000,000 7,038,897 D
Venker Eric President & Immunovant CEO 2025-09-22 Option exercise · Stock Option (Right to Buy) 10b5-1 −462,374 6,576,523 D
Venker Eric President & Immunovant CEO 2025-09-22 Option exercise · Stock Option (Right to Buy) 10b5-1 −100,000 6,476,523 D
Open-market sales · 1,711,000 sh · avg $14.92 · $25,524,777
Loading xslF345X05/form4.xml…